Wed Sep 25 03:18:47 UTC 2024: ## CareDx Stock Upgraded to “Buy” by StockNews.com

**[City, State] -** CareDx, Inc. (NASDAQ: CDNA) has received a positive upgrade from StockNews.com, moving from a “hold” rating to a “buy” rating. This follows a recent trend of positive analyst sentiment surrounding the company.

CareDx, which specializes in diagnostic solutions for transplant patients, has seen several other analysts adjust their ratings. Goldman Sachs raised their price target to $26.00 and maintained a “buy” rating, while BTIG Research upgraded to “buy” with a $40.00 price objective. Craig Hallum also boosted their price target to $32.00, maintaining a “buy” rating.

However, Wells Fargo & Company initiated coverage with an “underweight” rating and a $28.00 target price. Despite this outlier, the overall consensus for CDNA remains positive. MarketBeat.com reports an average rating of “Moderate Buy” with an average target price of $28.80.

CareDx exceeded analysts’ expectations in their recent quarterly earnings report, reporting a profit of $0.37 per share, significantly higher than the projected loss of $0.40. This positive performance could be contributing to the bullish outlook on the company’s stock.

Despite the positive outlook, insider activity has shown some selling pressure. Alexander L. Johnson, an insider at CareDx, sold a significant number of shares over several transactions in August. However, institutional investors and hedge funds have been increasing their holdings in the company, suggesting continued confidence in its future.

CareDx continues to develop and commercialize its diagnostic solutions for transplant patients, aiming to improve patient outcomes and reduce the risks associated with transplant procedures. The company’s focus on innovation and its positive financial performance are driving the optimistic sentiment among analysts.

**Disclaimer:** This article is based on publicly available information and should not be considered investment advice. Investors should conduct their own research before making any investment decisions.

Read More